

REMARKS

Claims 38-62 have been withdrawn. Claim 1 has been amended. Support for the amendments may be found throughout the specification. No new matter has been added. Claims 2, 4-7, and 31-34 have been cancelled without prejudice. Applicants reserve the right to prosecute the subject matter of the claims at a later date. Claims 1, 3, 8-30, 35-37, 63 and 64 are pending.

PRIORITY

A certified copy of UK 0224830.0 is enclosed to perfect the priority claim.

CLAIM REJECTIONS

Rejection of claims under 35 U.S.C. §102

Yoshino

The Examiner has rejected claims 1-37, 63 and 64 under 35 U.S.C. §102(b) as being anticipated by U.S. Patent No. 5,721,246 to Yoshino et al. ((1995) STN International HCPLUS database, Columbus (OH), accession number: 1995:713785) ("Yoshino"). See Office Action at page 3. Claims 2, 4-7, and 31-34 have been cancelled thus rendering this rejection moot with respect to those claims. Claims 3, 8-30, 35-37, 63 and 64 depend from independent claim 1.

The Examiner alleges that Yoshino "disclose[s] the synthesis of several heterocyclic sulfonamide derivatives and at least one of them anticipates the instantly claimed invention of formula I" See Office Action at page 3.

Yoshino does not describe the compound of Formula A wherein R₃ is H or a substituent; L is absent or is -CH₂-; wherein R₄ is selected from H and hydrocarbyl; wherein R₅ is an optionally substituted aryl ring; and wherein X is selected from S, O, NR₆ and C(R₇)(R₈), wherein R₆ is selected from H and hydrocarbyl groups, wherein each of R₇ and R₈ are independently selected from H and hydrocarbyl groups provided that the compound is other than the compounds disclaimed in amended claim 1.

Accordingly, independent claim 1 is not anticipated by Yoshino. Claims 3, 8-30, 35-37, 63 and 64 depend from claim 1 and are therefore patentable over Yoshino for at least the reasons described above. Applicants respectfully request reconsideration and withdrawal of this rejection.

Kitazawa

The Examiner has rejected claims 1-37 1-37, 63 and 64 under 35 U.S.C. §102(b) as being anticipated by U.S. Patent No. 6,579,881 to Kitazawa et al. ((1998): STN International HCPLUS database, Columbus (OH), accession number: 1998:682229) ("Kitazawa "). See Office Action at page 4. Claims 2, 4-7, and 31-34 have been cancelled thus rendering this rejection moot with respect to those claims. Claims 3, 8-30, 35-37, 63 and 64 depend from independent claim 1.

Kitazawa does not describe the compound of Formula A wherein R₃ is H or a substituent; L is absent or is -CH₂-; wherein R₄ is selected from H and hydrocarbyl; wherein R₅ is an optionally substituted aryl ring; and wherein X is selected from S, O, NR₆ and C(R₇)(R₈), wherein R₆ is selected from H and hydrocarbyl groups, wherein each of R₇ and R₈ are independently selected from H and hydrocarbyl groups provided that the compound is other than the compounds disclaimed in amended claim 1.

Accordingly, independent claim 1 is not anticipated by Kitazawa. Claims 3, 8-30, 35-37, 63 and 64 depend from claim 1 and are therefore patentable over Kitazawa for at least the reasons described above. Applicants respectfully request reconsideration and withdrawal of this rejection.

Arrhenius

The Examiner has rejected claims 1-37 1-37, 63 and 64 under 35 U.S.C. §102(b) as being anticipated by WO 02/066035 to Arrhenius et al. ((2002): STN International HCPLUS database, Columbus (OH), accession number: 2002:657951) ("Arrhenius "). See Office Action at page 4. Claims 2, 4-7, and 31-34 have been cancelled thus rendering this rejection moot with respect to those claims. Claims 3, 8-30, 35-37, 63 and 64 depend from independent claim 1.

Arrhenius does not describe the compound of Formula A wherein R₃ is H or a substituent; L is absent or is -CH₂-; wherein R₄ is selected from H and hydrocarbyl; wherein R₅ is an optionally substituted aryl ring; and wherein X is selected from S, O, NR₆ and C(R₇)(R₈), wherein R₆ is selected from H and hydrocarbyl groups, wherein each of R₇ and R₈ are independently selected from H and hydrocarbyl groups provided that the compound is other than the compounds disclaimed in amended claim 1.

Applicant : Nigel Vicker et al.
Serial No. : 10/690,708
Filed : October 23, 2003
Page : 15 of 15

Attorney's Docket No.: 15469.0003

Accordingly, independent claim 1 is not anticipated by Arrhenius. Claims 3, 8-30, 35-37, 63 and 64 depend from claim 1 and are therefore patentable over Arrhenius for at least the reasons described above. Applicants respectfully request reconsideration and withdrawal of this rejection.

CONCLUSION

Applicants believe that the claims are in condition for allowance. Should any fees be required by the present Amendment, the Commissioner is hereby authorized to charge Deposit Account **19-4293**.

Respectfully submitted,

Date: 8-8-06



Customer No. 27890
Steptoe & Johnson LLP
1330 Connecticut Avenue, NW
Washington, DC 20036-1795
Phone: 202-429-6748
Fax: 202-429-3902

Harold H. Fox
Reg. No. 41,498